A randomised controlled trial of secukinumab versus adalimumab for the treatment of juvenile idiopathic arthritis (JIA) associated uveitis or chronic anterior uveitis using a Bayesian design
Latest Information Update: 03 Mar 2023
At a glance
- Drugs Adalimumab (Primary) ; Secukinumab (Primary)
- Indications Anterior uveitis; Juvenile rheumatoid arthritis; Uveitis
- Focus Therapeutic Use
- Acronyms TURTLE
Most Recent Events
- 01 Mar 2023 Status changed from not yet recruiting to recruiting.
- 20 Feb 2023 New trial record